

Dan Greenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5630468/publications.pdf>

Version: 2024-02-01

132
papers

7,846
citations

126907
33
h-index

53230
85
g-index

135
all docs

135
docs citations

135
times ranked

11738
citing authors

#	ARTICLE	IF	CITATIONS
1	Normative data for the Brief Symptom Inventory for patients with Crohn's disease. Psychology and Health, 2022, 37, 246-257.	2.2	2
2	Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. Inflammatory Bowel Diseases, 2022, 28, 393-408.	1.9	21
3	The impact of a community-based heart failure multidisciplinary team clinic on healthcare utilization and costs. ESC Heart Failure, 2022, 9, 676-684.	3.1	4
4	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Journal of Medical Economics, 2022, 25, 1-7.	2.1	9
5	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ, The, 2022, 376, e067975.	6.0	141
6	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics, 2022, 40, 601-609.	3.3	39
7	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 2022, 25, 10-31.	0.3	251
8	Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease. Brain, Behavior, & Immunity - Health, 2022, 19, 100407.	2.5	11
9	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Public Health, 2022, 22, 179.	2.9	7
10	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, , 1-10.	0.9	0
11	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Services Research, 2022, 22, 114.	2.2	5
12	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. International Journal of Technology Assessment in Health Care, 2022, 38, e13.	0.5	78
13	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value in Health, 2022, 25, 3-9.	0.3	254
14	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy and Practice, 2022, 7, 238146832110610.	0.9	1
15	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Health Policy OPEN, 2022, 3, 100063.	1.5	11
16	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Medicine, 2022, 20, 23.	5.5	73
17	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Applied Health Economics and Health Policy, 2022, 20, 213.	2.1	12
18	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics, 2022, 23, 1309-1317.	2.8	9

#	ARTICLE	IF	CITATIONS
19	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 146-155.	0.9	3
20	Norton Scale Score and long-term healthcare services utilization after acute myocardial infarction. European Journal of Cardiovascular Nursing, 2022, 21, 702-709.	0.9	1
21	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Clinical Therapeutics, 2022, 44, 158-168.	2.5	22
22	It probably worked: a Bayesian approach to evaluating the introduction of activity-based hospital payment in Israel. Israel Journal of Health Policy Research, 2022, 11, 8.	2.6	0
23	Standardization of a Developmental Milestone Scale Using Data From Children in Israel. JAMA Network Open, 2022, 5, e222184.	5.9	13
24	Public legitimacy of healthcare resource allocation committees: lessons learned from assessing an Israeli case study. BMC Health Services Research, 2022, 22, .	2.2	3
25	The impact of gender on early scientific publication and long-term career advancement in Israeli medical school graduates. BMC Medical Education, 2021, 21, 163.	2.4	3
26	Factors associated with off-label (OL) drug use in oncology: The role of cost and financing in a universal healthcare system.. Journal of Clinical Oncology, 2021, 39, e18825-e18825.	1.6	0
27	Prospects of off-label (OL) drug use in oncology: Identifying predicting variables for registration and universal healthcare reimbursement.. Journal of Clinical Oncology, 2021, 39, e18842-e18842.	1.6	0
28	Dual Agency in Hospitals: What Strategies Do Managers and Physicians Apply to Reconcile Dilemmas Between Clinical and Economic Considerations?. International Journal of Health Policy and Management, 2021, , .	0.9	10
29	Effects of Activity-Based Hospital Payments in Israel: A Qualitative Evaluation Focusing on the Perspectives of Hospital Managers and Physicians. International Journal of Health Policy and Management, 2021, 10, 244-254.	0.9	4
30	Characteristics and economic burden of frequent attenders with medically unexplained symptoms in primary care in Israel. European Journal of General Practice, 2021, 27, 294-302.	2.0	4
31	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. Frontiers in Pharmacology, 2021, 12, 754390.	3.5	3
32	Mortality and healthcare resource utilization following acute myocardial infarction according to adherence to recommended medical therapy guidelines. Health Policy, 2020, 124, 1200-1208.	3.0	5
33	Associations between Subsequent Hospitalizations and Primary Ambulatory Services Utilization within the First Year after Acute Myocardial Infarction and Long-Term Mortality. Journal of Clinical Medicine, 2020, 9, 2528.	2.4	0
34	Early Atrial Fibrillation During Acute Myocardial Infarction May Not Be an Indication for Long-Term Anticoagulation. Angiology, 2020, 71, 559-566.	1.8	10
35	Temporal trends in healthcare resource utilization and costs following acute myocardial infarction. Israel Journal of Health Policy Research, 2020, 9, 6.	2.6	6
36	Sex and Ethnic Disparities in Health-Related Outcomes Following Acute Myocardial Infarction in Israel. Israel Medical Association Journal, 2020, 22, 303-309.	0.1	3

#	ARTICLE	IF	CITATIONS
37	Healthcare-service utilization and direct costs throughout ten years following acute myocardial infarction: Soroka Acute Myocardial Infarction II (SAMI II) project. Current Medical Research and Opinion, 2019, 35, 1257-1263.	1.9	2
38	What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria. Value in Health Regional Issues, 2019, 19, 157-162.	1.2	7
39	The study protocol for a randomized, controlled trial of acupuncture versus a sham procedure versus standard care alone for the treatment of delirium in acutely hospitalized older adults with a medical illness. Maturitas, 2019, 124, 72-80.	2.4	4
40	The 2010 expansion of activity-based hospital payment in Israel: an evaluation of effects at the ward level. BMC Health Services Research, 2019, 19, 292.	2.2	6
41	Budget Impact Analysis of Cancer Screening: A Methodological Review. Applied Health Economics and Health Policy, 2019, 17, 493-511.	2.1	6
42	Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. Heart, 2019, 105, 1487-1492.	2.9	3
43	Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 749-753.	1.4	2
44	Mass media effect on vaccines uptake during silent polio outbreak. Vaccine, 2018, 36, 1556-1560.	3.8	6
45	Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. Journal of Clinical Psychology, 2018, 74, 969-988.	1.9	12
46	Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn's Disease. International Journal of Behavioral Medicine, 2018, 25, 341-350.	1.7	13
47	Trajectories of Injectable Cancer Drug Costs After Launch in the United States. Journal of Clinical Oncology, 2018, 36, 319-325.	1.6	80
48	Lessons learned from the 2009-2010 H1N1 outbreak for the management of the 2013 silent polio outbreak. BMC Infectious Diseases, 2018, 18, 241.	2.9	1
49	Effect of Social Support on Psychological Distress and Disease Activity in Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2018, 24, 1389-1400.	1.9	27
50	Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 495-501.	1.4	1
51	Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2017, 29, 577-586.	1.6	5
52	Advancing the Visibility, Impact, and Quality Metrics of Value in Health Regional Issues. Value in Health Regional Issues, 2017, 13, 71-72.	1.2	0
53	Overuse of Head CT Examinations for the Investigation of Minor Head Trauma: Analysis of Contributing Factors. Journal of the American College of Radiology, 2017, 14, 171-176.	1.8	37
54	Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis. PLoS ONE, 2017, 12, e0172779.	2.5	28

#	ARTICLE	IF	CITATIONS
55	Simple pain measures reveal psycho-social pathology in patients with Crohn's disease. World Journal of Gastroenterology, 2017, 23, 1076.	3.3	9
56	Price trajectories assessment for Medicare Part B generic anti-cancer drugs.. Journal of Clinical Oncology, 2017, 35, 6624-6624.	1.6	1
57	Effect of psychosocial stressors on patients with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2016, 28, 1073-1081.	1.6	18
58	Cost-Effectiveness Analysis Expands its Reach Worldwide. Value in Health Regional Issues, 2016, 10, 101-102.	1.2	5
59	PCSK9 inhibitors may improve cardiovascular outcomes"Can we afford them?. International Journal of Cardiology, 2016, 220, 242-245.	1.7	13
60	Correlates of well-being among caregivers of long-term community-dwelling stroke survivors. International Journal of Rehabilitation Research, 2016, 39, 326-330.	1.3	21
61	Rethinking cost-effectiveness in the era of zero healthcare spending growth. International Journal for Equity in Health, 2016, 15, 33.	3.5	6
62	Cost-effectiveness of adherence-enhancing interventions: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 67-84.	1.4	24
63	The association between adherence to cardiovascular medications and healthcare utilization. European Journal of Health Economics, 2016, 17, 603-610.	2.8	11
64	Price trajectory of individual cancer drugs following launch.. Journal of Clinical Oncology, 2016, 34, 6502-6502.	1.6	4
65	High-Quality, Scientific Rigor, and Diversity: Value in Health Regional Issues Is Getting Its Impact. Value in Health Regional Issues, 2015, 7, 104-105.	1.2	0
66	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. Pharmacoeconomics, 2015, 33, 535-536.	3.3	7
67	Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort. Inflammatory Bowel Diseases, 2015, 21, 121-131.	1.9	47
68	Health-Related Utility Weights in a Cohort of Real-World Crohn's Disease Patients. Journal of Crohn's and Colitis, 2015, 9, 1138-1145.	1.3	11
69	Determinants of Cost-Related Nonadherence to Medications among Chronically Ill Patients in Maccabi Healthcare Services, Israel. Value in Health Regional Issues, 2014, 4, 41-46.	1.2	11
70	Is burnout associated with referral rates among primary care physicians in community clinics?. Family Practice, 2014, 31, 44-50.	1.9	64
71	What Are the Challenges in Conducting Cost-of-Illness Studies?. Value in Health Regional Issues, 2014, 4, 115-116.	1.2	25
72	Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach. European Journal of Health Economics, 2014, 15, 553-561.	2.8	11

#	ARTICLE	IF	CITATIONS
73	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. ClinicoEconomics and Outcomes Research, 2014, 6, 431.	1.9	13
74	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Effectiveness and Resource Allocation, 2013, 11, 6.	1.5	264
75	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Medicine, 2013, 11, 80.	5.5	185
76	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)â€™Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013, 16, 231-250.	0.3	1,657
77	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Pharmacoeconomics, 2013, 31, 361-367.	3.3	124
78	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in Health, 2013, 16, e1-e5.	0.3	513
79	Which Is More Valuable, Longer Survival or Better Quality of Life? Israeli Oncologistsâ€™™ and Family Physiciansâ€™™ Attitudes Toward the Relative Value of New Cancer and Congestive Heart Failure Interventions. Value in Health, 2013, 16, 842-847.	0.3	12
80	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Clinical Therapeutics, 2013, 35, 356-363.	2.5	17
81	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. European Journal of Health Economics, 2013, 14, 367-372.	2.8	191
82	Oncologistsâ€™™ and family physiciansâ€™™ views on value for money of cancer and congestive heart failure care. Israel Journal of Health Policy Research, 2013, 2, 44.	2.6	10
83	The case for orthopaedic medicine in Israel. Israel Journal of Health Policy Research, 2013, 2, 42.	2.6	6
84	How to make a right decision in health care: Multi criteria decision analysis in the healthcare system. , 2013,, , .		0
85	Note from the Editors. Value in Health Regional Issues, 2013, 2, 328.	1.2	0
86	Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa. Value in Health Regional Issues, 2013, 2, 169-170.	1.2	21
87	Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 513-522.	1.4	13
88	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Journal of Medical Economics, 2013, 16, 713-719.	2.1	18
89	CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT. International Journal of Technology Assessment in Health Care, 2013, 29, 117-122.	0.5	281
90	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ, The, 2013, 346, f1049-f1049.	6.0	1,082

#	ARTICLE	IF	CITATIONS
91	Temporal trends in patient characteristics and survival of intensive care admissions with sepsis. Critical Care Medicine, 2012, 40, 855-860.	0.9	40
92	Sa1256 Cost-Effectiveness of Episodic or Maintenance Infliximab Treatment Versus Standard Treatment in a Community-Based Incidence Cohort of Adult Ulcerative Colitis Patients With 10-Years Follow-up. Gastroenterology, 2012, 142, S-256.	1.3	3
93	Financial Risk-Sharing in Updating the National List of Health Services in Israel: Stakeholders' Perceived Interests. Value in Health, 2012, 15, 737-742.	0.3	8
94	Cost-Utility Analyses of Diagnostic Laboratory Tests: A Systematic Review. Value in Health, 2011, 14, 1010-1018.	0.3	39
95	Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: Results from the SAPHIRE trial. Catheterization and Cardiovascular Interventions, 2011, 77, 463-472.	1.7	37
96	Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 113-119.	1.4	8
97	Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?. International Journal of Cardiovascular Imaging, 2010, 26, 605-612.	1.5	28
98	A Bibliometric Review of Cost-Effectiveness Analyses in the Economic and Medical Literature: 1976-2006. Medical Decision Making, 2010, 30, 320-327.	2.4	21
99	The Adoption of Cost-Effectiveness Acceptability Curves in Cost-Utility Analyses. Medical Decision Making, 2010, 30, 314-319.	2.4	13
100	When is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology. Journal of the National Cancer Institute, 2010, 102, 82-88.	6.3	163
101	Is The United States Ready For QALYs?. Health Affairs, 2009, 28, 1366-1371.	5.2	69
102	The process of updating the National List of Health Services in Israel: Is it legitimate? Is it fair?. International Journal of Technology Assessment in Health Care, 2009, 25, 255-261.	0.5	25
103	Nutritional risk and health care use before and after an acute hospitalization among the elderly. Nutrition, 2009, 25, 415-420.	2.4	37
104	Estimating the budget impact of new technologies added to the National List of Health Services in Israel: Stakeholders'™ incentives for adopting a financial risk-sharing mechanism. Health Policy, 2009, 89, 78-83.	3.0	10
105	Much Cheaper, Almost as Good: Decrementally Cost-Effective Medical Innovation. Annals of Internal Medicine, 2009, 151, 662.	3.9	66
106	Patient adherence: a blind spot in cost-effectiveness analyses?. American Journal of Managed Care, 2009, 15, 626-32.	1.1	15
107	Peer Review in Publication: Factors Associated with the Full-Length Publication of Studies Presented in Abstract Form at the Annual Meeting of the Society for Medical Decision Making. Medical Decision Making, 2008, 28, 938-942.	2.4	24
108	Twenty Years of Cost-effectiveness Analysis in Medical Imaging: Are We Improving?. Radiology, 2008, 249, 917-925.	7.3	39

#	ARTICLE	IF	CITATIONS
109	Clinical trials and health economics – A marriage of convenience or a marriage made in heaven?. Journal of Medical Economics, 2008, 11, 541-546.	2.1	1
110	The costs and cost-effectiveness of an integrated sepsis treatment protocol. Critical Care Medicine, 2008, 36, 1168-1174.	0.9	127
111	When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature*. Critical Care Medicine, 2006, 34, 2738-2747.	0.9	119
112	Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses. Value in Health, 2006, 9, 213-218.	0.3	121
113	Bias in published cost effectiveness studies: systematic review. BMJ: British Medical Journal, 2006, 332, 699-703.	2.3	322
114	Using Health State Classification Systems for Utility Elicitation in the Elderly. Medical Decision Making, 2006, 26, 220-222.	2.4	1
115	Decisions to adopt new technologies at the hospital level: Insights from Israeli medical centers. International Journal of Technology Assessment in Health Care, 2005, 21, 219-227.	0.5	34
116	Diffusion of published cost-utility analyses in the field of health policy and practice. International Journal of Technology Assessment in Health Care, 2005, 21, 399-402.	0.5	14
117	Growth and Quality of the Cost-Utility Literature, 1976-2001. Value in Health, 2005, 8, 3-9.	0.3	136
118	Can We Better Prioritize Resources for Cost-Utility Research?. Medical Decision Making, 2005, 25, 429-436.	2.4	40
119	Quality of Abstracts of Papers Reporting Original Cost-Effectiveness Analyses. Medical Decision Making, 2005, 25, 424-428.	2.4	31
120	A synthesis of cost-utility analysis literature in infectious disease. Lancet Infectious Diseases, The, 2005, 5, 383-391.	9.1	15
121	Decisions to adopt new technologies at the hospital level: insights from Israeli medical centers. International Journal of Technology Assessment in Health Care, 2005, 21, 219-27.	0.5	9
122	Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis. BMJ: British Medical Journal, 2004, 328, 1536-1537.	2.3	17
123	Drug-eluting stent task force: Final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. Catheterization and Cardiovascular Interventions, 2004, 62, 1-17.	1.7	42
124	In-hospital Costs of Self-Expanding Nitinol Stent Implantation versus Balloon Angioplasty in the Femoropopliteal Artery (The VascuCoil Trial). Journal of Vascular and Interventional Radiology, 2004, 15, 1065-1069.	0.5	22
125	Can we afford to eliminate restenosis?. Journal of the American College of Cardiology, 2004, 43, 513-518.	2.8	95
126	Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy, 2004, 70, 207-216.	3.0	30

#	ARTICLE	IF	CITATIONS
127	Do the Benefits of New Technology Outweigh the Costs?. American Journal of Drug Delivery, 2003, 1, 255-266.	0.6	7
128	DECISION MAKING IN ACQUIRING MEDICAL TECHNOLOGIES IN ISRAELI MEDICAL CENTERS. International Journal of Technology Assessment in Health Care, 2003, 19, 194-201.	0.5	13
129	Implantable cardioverter defibrillators in Israel: utilization and implantation trends. International Journal of Cardiology, 2002, 82, 17-23.	1.7	10
130	Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. Clinical Research in Cardiology, 2002, 91, 137-143.	1.1	14
131	Preference-based outcome measures in cost-utility analyses. A 20-year overview. International Journal of Technology Assessment in Health Care, 2002, 18, 461-6.	0.5	11
132	Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel. Health Policy, 2001, 56, 49-63.	3.0	9